Successful Trovafloxacin Prophylaxis against Experimental Streptococcal Aortic Valve Endocarditis

AUTOR(ES)

Katsarolis, Ioannis

FONTE

American Society for Microbiology

RESUMO

Single-dose trovafloxacin (15 mg/kg given intravenously [i.v.]) and ampicillin (40 mg/kg given i.v.) protected 38 and 33% of animals challenged with an ampicillin-tolerant strain of Streptococcus oralis, respectively. As a double-dose regimen, trovafloxacin afforded total protection (100%; P < 0.001 versus controls). Trovafloxacin is the first fluoroquinolone effective in preventing experimental streptococcal endocarditis.

Documentos Relacionados

• Successful single-dose teicoplanin prophylaxis against experimental streptococcal, enterococcal, and staphylococcal aortic valve endocarditis.
• Single-Oral-Dose Azithromycin Prophylaxis against Experimental Streptococcal or Staphylococcal Aortic Valve Endocarditis
• Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis
• Efficacy of Trovafloxacin in Treatment of Experimental Staphylococcal or Streptococcal Endocarditis
• Chemotherapy of experimental streptococcal endocarditis. IV. Further observations on prophylaxis.